Exact Sciences
EXAS
#1154
Rank
C$26.77 B
Marketcap
C$141.08
Share price
-0.07%
Change (1 day)
60.70%
Change (1 year)
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.

Exact Sciences (EXAS) - Total debt

Total debt on the balance sheet as of September 2025 : C$3.51 Billion

According to Exact Sciences's latest financial reports the company's total debt is C$3.51 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exact Sciences - Total debt on balance sheet (from 2009 to 2025)

Total debt by year

Year Total debt Change
2024-12-31C$3.95 B16.66%
2023-12-31C$3.38 B2.05%
2022-12-31C$3.32 B9.37%
2021-12-31C$3.03 B2.16%
2020-12-31C$2.97 B138.25%
2019-12-31C$1.24 B32.85%
2018-12-31C$0.93 B16677.96%
2017-12-31C$5.59 M-24.19%
2016-12-31C$7.38 M-11.55%
2015-12-31C$8.34 M141.81%
2014-12-31C$3.45 M-25.74%
2013-12-31C$4.64 M128.66%
2012-12-31C$2.03 M99.82%
2011-12-31C$1.01 M1.76%
2010-12-31C$0.99 M-52.21%
2009-12-31C$2.09 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Myriad Genetics
MYGN
C$0.29 B-91.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Antares Pharma
ATRS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Veracyte
VCYT
C$56.47 M-98.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Biocept
BIOC
C$16.18 M-99.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
C$35.64 B 912.60%๐Ÿ‡ซ๐Ÿ‡ท France